journal article·2013-09

pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma

Yinsong Wang, Hongli Chen, Yuanyuan Liu, Jing Wu, Ping Zhou, Yan Wang, Rongshan Li, Xiaoying Yang, Ning Zhang

Biomaterials· Volume 34· Issue 29
Publisher page

Abstract

This study designs a pH-sensitive nanoparticle carrier of methotrexate (MTX) and combretastatin A4 (CA4) based on pullulan for the combination therapy against hepatocellular carcinoma (HCC). Briefly, N-urocanyl pullulan (URPA) with the degree of substitution (DS) of 5.2% was synthesized and then conjugated with MTX to form MTX-URPA, in which MTX content was 17.8%. MTX-URPA nanoparticles prepared by the dialysis method had spherical shape and the mean size of 187.1 nm, and showed high affinity for HepG2 cells. CA4 was successfully loaded into MTX-URPA nanoparticles and exhibited pH-sensitive in vitro release property. After intravenous injection to PLC/PRF/5-bearing nude mice, CA4 loaded MTX-URPA (CA4/MTX-URPA) nanoparticles achieved the enhanced antitumor and anti-angiogenic effects, the prolonged circulation time in blood, and the increased distributions both in the liver and the tumor. In conclusion, this drug carrier system has significant liver-targeting property and exhibits advantages for the combination therapy against hepatocellular carcinoma.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Hepatocellular Carcinoma Treatment and Prognosis · Multiple Myeloma Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (44)

Show source-provided references
1. Rising incidence of hepatocellular carcinoma in the United States10.1056/NEJM199903113401001 ↗
2. Hepatocellular carcinoma: from gene to public health10.1093/jnci/89.24.1844 ↗
3. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver10.1016/S0168-8278(01)00130-1 ↗
4. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival10.1053/jhep.2003.50047 ↗
5. Angiogenesis and tumor metastasis10.1146/annurev.med.49.1.407 ↗
6. Angiogenesis and hepatocellular carcinoma10.1016/j.jhep.2004.09.006 ↗
7. Role of angiogenesis in hepatitis and hepatocellular carcinoma
8. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma10.1016/j.canlet.2006.01.008 ↗
9. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results
10. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment10.1158/1535-7163.MCT-08-0715 ↗
11. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy10.1158/0008-5472.CAN-04-1668 ↗
12. Antiangiogenic therapy and tumor progression10.1016/S1535-6108(03)00336-2 ↗
13. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival10.3748/wjg.v11.i11.1705 ↗
14. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells
15. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy10.1038/nm0901-987 ↗
16. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy10.1126/science.1104819 ↗
17. Normalization of the vasculature for treatment of cancer and other diseases10.1152/physrev.00038.2010 ↗
18. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment10.1158/1541-7786.MCR-06-0002 ↗
19. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy10.1371/journal.pone.0006539 ↗
20. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system10.1038/nature03794 ↗
21. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature10.1016/j.nano.2011.05.003 ↗
22. Evidence for receptor-mediated hepatic uptake of pullulan in rats10.1016/S0168-3659(00)00368-0 ↗
23. Uptake of pullulan in cultured rat liver parenchymal cells10.1248/bpb.28.560 ↗
24. Liver targeting of plasmid DNA with a cationized pullulan for tumor suppression10.1166/jnn.2006.466 ↗
25. Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier10.1016/j.bmc.2010.04.031 ↗
26. Liver targeting of human interferon-beta with pullulan based on metal coordination10.1016/S0168-3659(02)00197-9 ↗
27. Liver targeting of interferon-beta with a liver-affinity polysaccharide based on metal coordination in mice10.1016/S0022-3565(24)29442-8 ↗
28. Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver10.1089/107999099314225 ↗
29. Liver targeting of interferon through pullulan conjugation10.1023/A:1016037225728 ↗
30. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin10.1021/bi00443a031 ↗
31. Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice10.1038/sj.cgt.7701116 ↗
32. Efficient gene delivery by urocanic acid-modified chitosan10.1016/j.jconrel.2003.08.017 ↗
33. Urocanic acid-modified chitosan-mediated p53 gene delivery inducing apoptosis of human hepatocellular carcinoma cell line HepG2 is involved in its antitumor effect in vitro and in vivo10.1016/j.bbrc.2008.10.023 ↗
34. Involvement of endothelial PECAM-1/CD31 in angiogenesis
35. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma10.1056/NEJM199101033240101 ↗
36. Sodium dodecyl sulphate-enhanced desorption of atrazine: effect of surfactant concentration and of organic matter content of soils10.1016/S0045-6535(99)00503-2 ↗
37. Structural characteristics of size-controlled self-aggregates of deoxycholic acid-modified chitosan and their application as a DNA delivery carrier10.1021/bc015510c ↗
38. Aggregation of hydrophobically modified polysaccharides in solution and at the air-water interface10.1016/j.jcis.2004.08.094 ↗
39. Self-assembled nanoparticles of cholesterol-modified O-carboxymethyl chitosan as a novel carrier for paclitaxel10.1088/0957-4484/19/14/145101 ↗
40. Pharmacokinetics and biodistribution of nanoparticles10.1021/mp800049w ↗
41. Factors affecting the clearance and biodistribution of polymeric nanoparticles10.1021/mp800051m ↗
42. Stability and in vivo evaluation of pullulan acetate as a drug nanocarrier10.3109/10717544.2010.490250 ↗
43. Self-assembled cationic nanogels for intracellular protein delivery10.1021/bc700422s ↗
44. Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy10.1016/j.colsurfb.2008.12.039 ↗